The short version
Just 2 companies supply this market — thin enough that a single exit would be felt immediately.
Market view
methyldopa · Powder
2 marketed package NDCs · 2 active manufacturers
Most dispensed: 250 mg · Tablet · #100 tablets/bottle · 250 mg · Tablet, Film Coated · #180 tablet, film coateds/bottle · 250 mg · Tablet, Film Coated · #90 tablet, film coateds/bottle
Same drug class
Other molecules FDA puts in Central alpha-2 Adrenergic Agonist, with whether each is in shortage right now. Same class is not the same drug — substitution is a clinical decision, and this is a supply picture, not a recommendation.
- dexmedetomidine hcl· in shortage
- dexmedetomidine hydrochloride in 0.9% sodium chloride· in shortage
- dexmedetomidine· in shortage
- dexmedetomidine hydrochloride· in shortage
- clonidine hci· 1 maker
- clonidine hydrochloride oral· 1 maker
- dexmedetomidine hydrochloride in sodium chloride· 1 maker
- tizandine· 1 maker
- clonidine transdermal system· 2 makers
- guanfacine er· 2 makers
- tizanidine hcl· 2 makers
- gaunfacine· 3 makers
Common questions
- Is Methyldopa in shortage right now?
- No. FDA does not currently list Methyldopa in shortage. This page is rebuilt every morning from FDA's shortage database, so a new posting appears here the day it is published.
- Who makes Methyldopa?
- 4 companies have marketed Methyldopa in the last 30 days, according to the FDA NDC Directory. Every manufacturer and package is listed on this page.
All marketed products
Expand a strength to see its dosage forms, then package sizes, then each manufacturer and NDC. Click an NDC for its full detail page.